U.S. stocks fell, while BKV surged 9.2% on an equipment contract announcement; Penguin Solutions led

Verastem is performing commercially with Avmapki Fakzynja Co-pack and advancing in the clinic with i

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to

Verastem (NASDAQ: VSTM - Get Free Report)'s stock had its "buy" rating reiterated by stock analysts

Verastem (NASDAQ: VSTM - Get Free Report)'s stock had its "buy" rating reissued by stock analysts at

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Verastem (NASDAQ:VSTM) with a Buy

RAMP 201 molecular profiling showed clinically meaningful activity in KRAS wild-type recurrent LGSOC

BOSTON--(BUSINESS WIRE)---- $VSTM #CancerResearch--New RAMP 201 Molecular Profiling and External Con

Verastem (NASDAQ: VSTM - Get Free Report) and Sangamo Therapeutics (NASDAQ: SGMO - Get Free Report)

BOSTON--(BUSINESS WIRE)---- $VSTM #CancerResearch--Long-term RAMP 201 results published in Gynecolog

BOSTON--(BUSINESS WIRE)---- $VSTM #CancerResearch--Verastem to present late-breaking oral presentati

Shares of Verastem, Inc. (NASDAQ: VSTM - Get Free Report) rose 7.1% during trading on Tuesday. The c

Verastem NASDAQ: VSTM executives outlined the company's commercial and clinical priorities at an H.C

Verastem, Inc. (NASDAQ: VSTM - Get Free Report) has been given an average rating of "Moderate Buy" b

Bank of New York Mellon Corp acquired a new stake in shares of Verastem, Inc. (NASDAQ: VSTM) in the

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Verastem (NASDAQ:VSTM) with a Buy

VSTM shares surge 121% as Avmapki Fakzynja Co-Pack gains commercial traction and VS-7375 advances ac

Investor event and webcast to be held Wednesday, October 14, 2026, at 8:00 am ETVerastem Oncology (N

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to

Verastem is evolving from a speculative biotech into a commercially validated precision oncology com

Shares of Verastem, Inc. (NASDAQ: VSTM - Get Free Report) have earned a consensus rating of "Moderat

Mizuho analyst Graig Suvannavejh maintains Verastem (NASDAQ:VSTM) with a Outperform and lowers th

Verastem NASDAQ: VSTM reported second-quarter 2026 net product revenue of $25.1 million from sales o

Guggenheim analyst Michael Schmidt maintains Verastem (NASDAQ:VSTM) with a Buy and lowers the pri

Verastem, Inc. (VSTM) Q2 2026 Earnings Call Transcript

Verastem (VSTM) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimat

Verastem (NASDAQ:VSTM) reported quarterly losses of $(0.35) per share which beat the analyst consens

Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines fo

Gainers Tenet Healthcare (NYSE:THC) shares rose 14.1% to $227.06 during Thursday's after-market

TARGET-D 202 (NCT07659782) is a global, open-label, Phase 2 registration-directed trial evaluating V

Seven small-cap stocks have surged as much as 123% in early July on buyouts, FDA developments, refin

RBC Capital analyst Leonid Timashev maintains Verastem (NASDAQ:VSTM) with a Outperform and lowers

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Verastem (NASDAQ:VSTM) with a Buy

Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines fo

Verastem updated RAMP 205 data showed 86% six-month survival in metastatic pancreatic cancer and con

90% of patients in the study presented with metastatic (Stage IV) disease at diagnosis6-month overal

Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines fo

Featuring updated preliminary clinical data across tumor types from the Phase 1/2 TARGET-D 101 trial

Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines fo

Mizuho analyst Graig Suvannavejh maintains Verastem (NASDAQ:VSTM) with a Outperform and lowers th

BTIG analyst Jeet Mukherjee maintains Verastem (NASDAQ:VSTM) with a Buy and lowers the price tar

Verastem (NASDAQ:VSTM) reported quarterly losses of $(0.43) per share which beat the analyst consens

Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines fo

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Verastem (NASDAQ:VSTM) with a Buy

Plenary oral presentation features long-term follow-up data from the Phase 2 RAMP 201 recurrent low-

Verastem (NASDAQ:VSTM) reported quarterly losses of $(0.48) per share which beat the analyst consens